RA patients assigned to yoga plus DMARD therapy also had a drop in depression symptoms
WEDNESDAY, Feb. 13, 2019 (HealthDay News) — Yoga may be effective as a complementary or adjunct therapy for patients with rheumatoid arthritis (RA) taking disease-modifying antirheumatic drugs (DMARDs), according to a study published online Feb. 1 in Restorative Neurology and Neuroscience.
Surabhi Gautam, from the All India Institute of Medical Sciences in New Delhi, and colleagues assessed the effect of a yoga-based mind-body intervention on disease-specific inflammatory markers and depression severity. The authors randomly assigned 72 patients with active RA on routine DMARD therapy to a yoga group (yoga with DMARDs) or a control group (DMARDs only).
The researchers found that after eight weeks, the yoga group had a significant decrease in the severity of RA, measured by lower levels of various systemic inflammatory markers as well as decreases in disease activity score 28 erythrocyte sedimentation rate and health assessment questionnaire disability index scores. Further, within the yoga group, there was a statistically significant time-dependent, stepwise drop in depression symptoms compared with the control group.
“This study offers a new option,” a coauthor said in a statement. “Pharmacological treatments can be supplemented with alternative and complementary interventions like yoga to alleviate the symptoms at both physical and psychosomatic levels.”
Abstract/Full Text (subscription or payment may be required)
Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis